In a shift toward venture capital fundraising, FORMA brings in $100 million
After eschewing venture capital for the better part of a decade, Watertown-based FORMA Therapeutics is changing its tune.
Related Articles
Pharmalittle: We’re reading about tariffs increasing U.S. drug costs, Trump cuts on drug safety, and more
Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting prices as much as 12.9%
This health tech exec is in charge of Medicare, and he has big ambitions
A close look at Chris Klomp’s path to the top of Medicare, which pays for the health care of 68 million Americans.
Major tuberculosis vaccine trial completes enrollment faster than expected
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of…
Therapy and poetry have more in common than you think
“Confounded by a confusing expression or dream from a patient, I might seemingly shift gears and ask myself, ‘What if this were a poem?’” writes…
Our 7 biggest questions as Congress returns to work
As Congress returns to work, STAT is tracking what health spending will get cut and when RFK Jr. will testify.
Nurse-scientists shouldn’t have to choose between research and caring for patients
While physician-scientists are supported in splitting their time between research and clinical work, nurse-scientists are not.
Merck KGaA to purchase SpringWorks Therapeutics in deal worth more than $3 billion
After months of discussion, Germany’s Merck KGaA said it would buy SpringWorks Therapeutics.
U.S. health officials inject new uncertainty into approval process for Covid boosters
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible implications for Pfizer and Moderna.
‘Fight for your science’: Researchers urged to speak out at AACR
“We are navigating political interference, institutional instability, and growing uncertainty across the cancer research enterprise”: At AACR, cancer researchers are speaking up.